Phase II, Multi-center Trial of Nivolumab and Brentuximab Vedotin in Patients with Untreated Hodgkin Lymphoma Over the Age of 60 Years or Unable to Receive Standard Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) Chemotherapy

Type of Cancer
Lymphoma

Sponsor
accru

Protocol Number
ACCRU RU051505i (Nivo)

To Learn More Call
(201)-510-0950